Abstract
Introduction

Coronary heart disease (CHD) is a major cause of morbidity and mortality in patients with type 2 diabetes, with the incidence of cardiovascular disease in diabetic patients being twice that of nondiabetic men and three times that of non-diabetic women
. More recent estimates suggest that women in the age group of [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] years are five times more likely to have a myocardial infarction than women without diabetes [2] . Interventions such as a coronary artery bypass graft (CABG) surgery, are also associated with a significantly lower 5-year survival in diabetic patients than in non-diabetic with increased post-operative and long-term morbidity [3] [4] [5] . Furthermore, diabetic patients who survive an MI are more likely to develop heart failure than non-diabetic patients [6] . Therefore, new cardioprotective strategies which are capable of protecting the diabetic myocardium are required in order to improve clinical outcomes in diabetic patients with CHD. [7] . However, experimental animal studies suggest that the diabetic heart may be resistant to the cardioprotective effects of IPC [8] , and this may be the case in diabetic patients [9, 10] . An experimental study from our laboratory suggests that a more robust IPC stimulus is used, the diabetic heart is still amenable to the infarct-limiting effects of IPC [11] . The apparent resistance of the diabetic heart to a standard IPC protocol may be attributed to down-regulation of the PI3K-Akt pathway [11] , a major component of the signal transduction pathway which underlies IPC [12, 13] , as demonstrated in previous experimental animal studies [14] . In the current study we investigate whether myocardial tissue harvested from diabetic patients undergoing CABG is amenable to the cardioprotection elicited by IPC. 
In this respect, the endogenous cardioprotective phenomenon of ischaemic preconditioning (IPC) represents a powerful interventional strategy for protecting against myocardial injury arising from ischaemia-reperfusion injury. IPC is elicited by brief non-lethal episodes of myocardial ischaemia and reperfusion applied before the lethal ischaemic insult
Materials and methods
Study patients
The human atrial trabecula model of simulated ischaemia-reperfusion injury
This experimental model was first established in our research laboratory and is both a robust and reproducible technique for assessing cardioprotective treatment strategies using human atrial trabeculae subjected to simulated ischaemia-reperfusion injury [17, 18] [17, 18] .
The atrial trabeculae harvested from patients were randomized to the following groups ( Fig. 1 
Western blot analysis
Right atrial appendages from non diabetic (n ϭ 4) and diabetic (n ϭ 5) patients, were immediately frozen after being excised from the heart at the time of CABG surgery. They were stored in a -80ЊC freezer and were subsequently analysed for phosphorylation of Akt (serine 473) and normalized to the total Akt level. Equal loading was confirmed by probing for ␤-actin levels. SDS-PAGE immunoelectrophoresis was used to determine this along with primary and secondary antibodies obtained from New England
Bio Labs (Ipswich, MA, USA) as previously described [12] . 
Statistical analysis
Results
Diabetic myocardium requires a stronger preconditioning stimulus
There were no significant differences in the contractile functions of the atrial trabeculae at baseline ( (Fig. 3) . [11] . Interestingly, the resistance of the diabetic rat heart following the standard IPC protocol of one cycle was attributed to insufficient activation of the PI3K-Akt pathway, whereas the three cycles of IPC succeeded in limiting myocardial infarct size, as the PI3K-Akt pathway was sufficiently activated [11] , suggesting a threshold level of kinase activity which needs to be achieved to confer cardioprotection in the setting of IPC. In contrast, Ghosh and colleagues [9] 
failed to precondition human right atrial appendages obtained from type 2 diabetic patients despite applying repeated cycles of hypoxia and reoxygenation. This discordant result may be attributed to that fact that the experimental model used in their study differs considerably from the one used by our laboratory. In their study the entire right atrial appendage sample is cut into thin slices and the whole specimen is immersed in hypoxic buffer and subjected to simulated ischaemia-reperfusion injury, at the end of which the amount of
Fig. 2 Standard hypoxic preconditioning (HPC -4 min. hypoxia and 16 min. reoxygenation) results in better recovery of function compared to the control group in non-diabetic trabeculae (*P Ͻ 0.005; n ϭ 6/group). The standard HPC protocol fails to protect diabetic trabeculae (n ϭ 6) but a prolonged HPC protocol (7 min. hypoxia and 16 min. reoxygenation; n ϭ 7) results in significantly better recovery of function compared to the control group (n ϭ 8) (**P Ͻ 0.005). However, there is also a significant difference between the standard HPC in the non-diabetic trabeculae and the prolonged HPC in the diabetic trabeculae, suggesting that there may be room for further protection (***P Ͻ 0.05).
Fig. 3 In diabetic myocardium, phospho-Akt is significantly lower when compared to non-diabetic myocardium (*P Ͻ 0.05). Note that the tenth blot shown in the Western blotting strip at the top of the figure is a positive control in an insulin stimulated mouse heart harvested a few minutes into reperfusion (A). There is no significant difference in the total Akt, normalized to ␤-actin, between diabetic and non diabetic myocardium (*P ϭ 0.11). The ␤-actin blots in the strip at the top of the figure suggest equal loading in all wells. Once again, the tenth blot in the total Akt strip is a positive control in an insulin stimulated mouse heart harvested a few minutes into reperfusion. The ␤-actin signal in the insulin stimulated mouse heart was too weak to be picked up at the exposure required for human myocardium (B). Values on the y-axis are in arbitrary units.
CK released is used to assess cardioprotection [9] [19] . In other more reliable models of type 2 diabetes such as the lean Goto-Kakizaki (GK) and the Zucker diabetic fatty rats, IPC did not offer any protection [20] , just as in diabetic animal models of the dog, the rabbit and the sheep. If anything, outcome seemed to worsen in the larger animal models [8] .
In the clinical setting, IPC is known to be more difficult in diabetic patients than in non-diabetic patients. Ishihara et al. studied 611 patients presenting with their first AMI, of whom 121 had diabetes. They noted that the onset of prodromal angina 24 hrs prior to the AMI was associated with a lower CK level after procedure, higher left ventricular ejection fractions and lower in hospital mortality in non-diabetic patients. Diabetic patients, on the other hand, did not benefit from the onset of angina, with no change in the three mentioned parameters [10] . The authors suggested that this may be due to a number of reasons: diabetic hearts may have an altered KATP channel [21] ; acute hyperglycaemia has been shown to abolish IPC [22] and oral hypoglycaemic agents like glibenclamide which block KATP channel opening can prevent IPC [16] . In addition, it is also known that the initial steps of insulin signalling and glucose transport are defective in the type 2 diabetic heart [23] , steps which may be inherent to insulin mediated IPC [24] . Furthermore, basal protein kinase B levels and insulin stimulated Akt, ERK and PI3-K have been shown to be defective in diabetic animals [14, 25] . Mitochondrial dysfunction has also been suggested as a potential reason for failure to precondition the human diabetic myocardium [26] . Hassouna [29, 30] . It has been suggested that the cardioprotective effects of metformin could be attributable to actions other than glucose lowering, specifically, through the activation of AMP-activated protein kinase (AMPK), an enzyme regulating lipid and glucose metabolism [31] . In fact, the acute administration of metformin in low doses has been shown to activate AMPK-eNOS in diabetic and non-diabetic murine hearts, while causing infarct size reduction following ischaemiareperfusion injury [32] . However, the effect of chronic metformin therapy on the activity of AMPK has not been demonstrated.
Of the 13 diabetic patients consented for our study, 6 patients were on sulphonylureas, which are thought to inhibit mitochondrial KATP channels that may inhibit the cardioprotection elicited by preconditioning. However, the role of the mitochondrial KATP channel in IPC has not been established without doubt [33, 34] . Furthermore, some sulphonylureas such as gliclazide have been shown to be more selective for pancreatic mitochondrial KATP channels as opposed to myocardial channels [35] . Indeed it has been shown that newer sulphonlyureas, such as gliclazide and glimepiride, do not abolish IPC in rats whereas glibenclamide does [16, 36, 37] . Four patients were prescribed gliclazide which, incidentally, has been shown to inhibit preconditioning using supramaximal doses in human atrial muscle [38] . Two patients were on glipizide, which does not inhibit myocardial preconditioning in rabbits in vivo [39] [40] , as has shown to be the case with chronic atorvastatin administration by our group [41, 42] .
A In conclusion, the present study demonstrates for the first time that myocardium from diabetic patients can be preconditioned ex vivo; however, the threshold for protection is raised. The findings from the current study suggest that diabetic patients are still amenable to the benefits of IPC but that they may require a stronger preconditioning stimulus compared to non-diabetic patients.
